USA flag logo/image

An Official Website of the United States Government

MODIFIED TNF-ALPHA: AN ANTI CANCER THERAPY

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
53773
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43CA085023-01A2
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PHOENIX PHARMACOLOGICS, INC.
PHOENIX PHARMACOLOGICS, INC. ASTECC FACILITY #A-217 LEXINGTON, KY 40506
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: MODIFIED TNF-ALPHA: AN ANTI CANCER THERAPY
Agency: HHS
Contract: N/A
Award Amount: $99,962.00
 

Abstract:

DESCRIPTION (PROVIDED BY APPLICANT): The long-term goal of the proposed research is the development of effective anti-cancer agents, modified human tumor necrosis factor-alphas (hTNFas). TNFa is a potent anti-neoplastic agent but its therapeutic application has been limited by its significant side effects. However, TNFa can be modified so that it retains its anti-tumor activities while its deleterious effects are reduced. This has been accomplished by mutation of TNFa and derivitization of TNFa with polyethylene glycol (PEG). This proposal focuses on the characterization and comparison of mutant and wild hTNFas modified with 20 kDa PEGs. The specific aims are to: 1) pharmacologically characterize the PEG-hTNFas, toxicity analyses after a single high dose of PEG-TNFa and a prolonged PEG-TNFa treatment; 2) define TNFa anti-cancer features, analyses of: a)anti-tumor efficacies in syngeneic and athymic mice with B16 melanomas, b)affinities of the PEG- hTNFas for hTNF receptors I and II (prerequisite for clinical trials); and 3) determine the anti-human tumor efficacies of these PEG-hTNFas, treatment of athymic mice bearing human colon carcinomas. PROPOSED COMMERCIAL APPLICATION: This proposal focuses on the development of new therapeutic agents, PEG-hNTFas effective against a wide range of solid tumors. Novel geatures of modified hTNFas include the likelihood of a marked synergy with cytotoxic chemotherapeutic agents and the potential to target the tumor vasculature and the host immune system.

Principal Investigator:

Mike A. Clark

Business Contact:


8592579027
MCLARL@POP.UKY.EDU
Small Business Information at Submission:

PHOENIX PHARMACOLOGICS
ASTECC FACILITY #A-217 UNIVERSITY OF KENTUCKY LEXINGTON, KY 40506

EIN/Tax ID: 232927291
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No